Coming Soon: A Highly Effective New Vaccine to Prevent Shingles
Approximately one million cases of shingles are reported annually in the U.S., and half of individuals over age 85 years are likely to develop shingles. The need for a vaccine that can provide protective immunity against shingles and PHN in older at-risk adults is clear.
C.Diff Vaccine Shows Promise in Phase II Trial
Results of a Phase II clinical trial ofPfizer’s preventive vaccine againstClostridium difficile (C. diff) showed the vaccine was safe and stimulated a C. diff targeted immune response.
CDC Changes Recommendation for HPV Vaccine for Children
The Advisory Committee on Immunization Practices has changed its recommendation for the human papilloma virus from three doses to two doses of the vaccine prior to age 15.
Scientists Develop Vaccine to Block Opioid Drugs’ Effects
A new vaccine that blocks the pain-numbing effects of the drugs oxycodone and hydrocodone has shown success in animal models.
No Link Between Flu or Flu Vaccine and Autism, Study Finds
A new study shows that babies of pregnant women who get the flu or who are vaccinated against the flu do not have an increased risk for Autism Spectrum Disorder.
Study Identifies Why TB Vaccines Are Ineffective
Researchers at the Washington University School of Medicine in St. Louis have discovered the reason the BCG vaccine and investigational vaccine candidates are not more effective.
FDA Approves First Human Trial of a Zika Vaccine
The U.S. Food and Drug Administration has approved the first human trial of an experimental Zika virus vaccine.
Study Finds Influenza Vaccine’s Effectiveness Can Be Improved
Research conducted at the University of Texas at Austin found that how the influenza (flu) vaccine produces antibodies to protect against disease could be used to improve the vaccine.
Vaccine for Lung Cancer Approved for Clinical Trial
A lung cancer vaccine developed in Cuba has been approved by the U.S. Food and Drug Administration for a clinical trial at Roswell Park Cancer Institute in Buffalo, N.Y.
GSK’s Shingles Vaccine Effective in Adults 70-Plus Years Old
A randomized Phase III study (ZOE-70) of GlaxoSmithKline’s investigational shingles vaccine, Shingrix, showed 90 percent efficacy in adults aged 70 years and older that is maintained for at least four years.